Valneva Reports Successful Outcome of Phase 2 Run-In for its Lyme Disease Vaccine Candidate

Based on DSMB clearance, two lead dosage levels have been selected for ongoing Phase 2 clinical development

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced progress of its ongoing Phase 2 study for its leading, unique Lyme disease vaccine candidate, VLA15, into the main study phase. An independent Data Safety Monitoring Board (DSMB) has cleared two dosage levels to be used for clinical development. 

Read more